Prioritizing Mental Health in South African Medical Schemes: Challenges and Opportunities

By HEOR Staff Writer

May 1, 2023

Medical schemes in South Africa are prioritizing mental health as a key component of managed care services. In 2019 CMS published a PMB definition guidelines for mental health emergencies.

“It is still concerning that beneficiaries of medical schemes attracted copayments as high as five (5%) for services such as a psychiatry benefit. Prior studies have also found that medical scheme members affected by mental illness and in most cases were discriminated against by funders. There needs to be a concerted effort to reprioritise mental health,” said Willie

A study analysed data from 2014-2018 and found the most prevalent mental disorders in South Africa in 2017 were anxiety and depression. However, only schizophrenia and bipolar mood disorder are the only conditions included in the PMB Chronic Diseases List (CDLs).

It is worrying that mental disorders like depression and anxiety are not covered under PMBs. We need a review of PMBs to include these conditions. A designated medical scheme provider should consider resource scarcity and co-payment rules.

Reference url

Recent Posts

Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovascular Disease in Europe

By João L. Carapinha

April 23, 2026

Europe loses approximately €240 billion every year because of the interconnected burdens of obesity diabetes cardiovascular disease (EFPIA Guest Blog). Fragmented healthcare systems that treat late-stage complications instead of preventing disease progression are largely responsible for this mass...
Zanidatamab Biliary Cancer Therapy: Advancing Targeted Treatment for HER2-Positive Patients
Zanidatamab biliary cancer therapy has been recommended by NICE for routine use in the NHS to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who have received at least one prior line of systemic therapy. Targeted Option for Rare Aggre...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically Suppressed Patients
The FDA has approved Merck’s HIV two-drug regimen, IDVYNSO™ (doravirine/islatravir), the first and only non-integrase strand transfer inhibitor (non-INSTI), tenofovir-free, once-daily complete regimen for adults with virologically suppressed HIV-1 infection. First Non-INSTI, Tenofovi...